摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-dimethylamino-2-(4-nitrophenyl)-2-propenal | 84462-79-3

中文名称
——
中文别名
——
英文名称
3-dimethylamino-2-(4-nitrophenyl)-2-propenal
英文别名
3-(Dimethylamino)-2-(4-nitrophenyl)-2-propenal;(E)-3-(dimethylamino)-2-(4-nitrophenyl)prop-2-enal
3-dimethylamino-2-(4-nitrophenyl)-2-propenal化学式
CAS
84462-79-3;85907-56-8
化学式
C11H12N2O3
mdl
——
分子量
220.228
InChiKey
CORSHMOZKWMERI-YFHOEESVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    131 °C
  • 沸点:
    460.7±40.0 °C(Predicted)
  • 密度:
    1.202±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    66.1
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    与氨力农相关的新型强心剂:1,2-二氢-5-芳基吡啶-2-酮的合成
    摘要:
    为了开发新的强心剂,由甲基喹啉、2-芳基乙酸或3-芳基乙酮通过直接氨基亚甲基化和随后的缩合制备了一系列与氨力酮相关的5-芳基-3,4-二氢吡啶-2(1H)-酮-在经典碱性介质或相转移催化中与丙二酰胺和氰乙酰胺环化,收率良好。初步药理试验表明,这些化合物,尤其是 5h 和 5i,具有显着的强心作用,对从猫心脏中分离的 PDE-III/PDE-I 具有选择性抑制作用。
    DOI:
    10.1002/ardp.19923250807
  • 作为产物:
    参考文献:
    名称:
    与氨力农相关的新型强心剂:1,2-二氢-5-芳基吡啶-2-酮的合成
    摘要:
    为了开发新的强心剂,由甲基喹啉、2-芳基乙酸或3-芳基乙酮通过直接氨基亚甲基化和随后的缩合制备了一系列与氨力酮相关的5-芳基-3,4-二氢吡啶-2(1H)-酮-在经典碱性介质或相转移催化中与丙二酰胺和氰乙酰胺环化,收率良好。初步药理试验表明,这些化合物,尤其是 5h 和 5i,具有显着的强心作用,对从猫心脏中分离的 PDE-III/PDE-I 具有选择性抑制作用。
    DOI:
    10.1002/ardp.19923250807
点击查看最新优质反应信息

文献信息

  • 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones,
    申请人:Sterling Drug Inc.
    公开号:US04465686A1
    公开(公告)日:1984-08-14
    Disclosed and claimed is the cardiotonic use of 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (II), where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R" are each hydrogen, amino or hydroxy, at least one of R' or R" being other than hydrogen, or where R' is nitro when R" is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R" is amino. Also disclosed and claimed are 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (I), where R.sub.1, R' and R" are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R" is amino. Also shown and claimed is the process which comprises reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-(3-R'-4-R"-phenyl)-6-R-nicotinonitrile, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R" is hydroxy, methoxy or hydrogen, preferably at least one of R' and R" being methoxy, or where R' is nitro and R" is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinone.
    揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮(II)的强心作用,其中R.sub.1为氢、低烷基或低羟基烷基,R为低烷基或氢,R'和R"分别为氢、氨基或羟基,其中至少有一个R'或R"不是氢,或者当R"为羟基时,R'为硝基,或其药学上可接受的酸加合物盐,其中至少一个R'和R"为氨基。还揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮(I),其中R.sub.1、R'和R"的定义如上所述,R为低烷基,以及其药学上可接受的酸加合物盐,其中至少一个R'和R"为氨基。还显示和声明了一种过程,包括将1-R.sub.1 -1,2-二氢-2-氧代-5-(3-R'-4-R"-苯基)-6-R-烟酸腈与85%磷酸反应,其中R.sub.1和R的定义如上所述用于II,R'为氢、羟基、甲氧基或氨基,R"为羟基、甲氧基或氢,最好是R'和R"中至少一个为甲氧基,或者当R'为硝基且R"为氢或甲氧基时,最好为甲氧基,以产生1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮。
  • 3-Amino-5-(hydroxy- and/or
    申请人:Sterling Drug Inc.
    公开号:US04515797A1
    公开(公告)日:1985-05-07
    1-R.sub.1 -3-amino-5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones or salts thereof, which are useful as cardiotonics, where R.sub.1 is hydrogen, lower-alkyl, or lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and, R' and R" are each hydrogen, hydroxy or amino at least one of R' or R" being other than hydrogen, are prepared by reacting the corresponding 3-carbamyl compound with a reagent capable of converting carbamyl to amino or by first reacting the corresponding 3-carbamyl compound where R' and R" are each hydrogen, nitro or lower-alkoxy at least one of R' and R" being other than hydrogen with a reagent capable of converting carbamyl to amino and then reacting the resulting 3-amino compound where R' and/or R" are/is lower-alkoxy and/or nitro with a reagent capable of converting lower-alkoxy to hydroxy and/or with a reagent capable of converting nitro to amino. Preparation of the corresponding 3-carbamyl and 3-cyano compounds is shown, the latter including cardiotonically active novel 1-R.sub.1 -1,2-dihydro-5-(3-R.sub.2 -4-R.sub.3 -phenyl)-6-R-nicotinonitriles where R.sub.1 and R are defined as above, and R.sub.2 and R.sub.3 have the above given definitions for R' and R" or where R.sub.2 is nitro and R.sub.3 is hydroxy. Also shown are cardiotonic compositions and cardiotonic method of use of above-said compounds.
    1-R.sub.1 -3-氨基-5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮或其盐,可用作心脏强心剂,其中R.sub.1是氢、低烷基或低羟基烷基,R是氢或低烷基,R'和R"分别是氢、羟基或氨基,其中R'或R"至少有一个不是氢,通过将相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应制备,或者首先将R'和R"分别是氢、硝基或低烷氧基,其中R'和R"中至少有一个不是氢的相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应,然后将所得的3-氨基化合物与能够将低烷氧基转化为羟基和/或能够将硝基转化为氨基的试剂反应,其中R'和/或R"是低烷氧基和/或硝基。显示了相应的3-氨基甲酰和3-氰基化合物的制备,后者包括具有心脏强心活性的新颖的1-R.sub.1 -1,2-二氢-5-(3-R.sub.2 -4-R.sub.3 -苯基)-6-R-烟酰腈,其中R.sub.1和R如上所定义,R.sub.2和R.sub.3具有上述给定的R'和R"的定义,或者其中R.sub.2是硝基,R.sub.3是羟基。还显示了心脏强心剂组合物和上述化合物的心脏强心方法的用途。
  • Substituted 3-alkyl-6-phenyl-1,2,4-triazolo(4,3-a)pyridines, processes for their preparation and pharmaceutical compositions containing them
    申请人:AMERICAN CYANAMID COMPANY
    公开号:EP0017438A1
    公开(公告)日:1980-10-15
    There are provided novel 3-alkyl-6-(substituted-phenyl)-1,2,4-triazolo[4,3-a]pyridines useful as anxiolytic agents, processes for their preparation and pharmaceutical compositions containing them. The compounds have the formula: wherein R, is hydrogen, alkyl (C1-C4), alkoxy (C,-C4), fluoro, chloro, bromo, trifluoromethyl, cyano, carboxy, alkoxycarbonyl (C2-C5), carboxamido, nitro, amino, acylamino (C1-C4), monoalkylamino (C1-C4) or dialkylamino wherein each alkyl group has up to 4 carbon atoms and R2 is alkyl (C1-C3); or a pharmacologically acceptable acid-addition salt thereof.
    本发明提供了可用作抗焦虑剂的新型 3-烷基-6-(取代苯基)-1,2,4-三唑并[4,3-a]吡啶、其制备工艺以及含有这些化合物的药物组合物。这些化合物的化学式如下 其中 R,是氢、烷基(C1-C4)、烷氧基(C,-C4)、氟、氯、溴、三氟甲基、氰基、羧基、烷氧羰基(C2-C5)、羧酰胺基、硝基、氨基、酰氨基(C1-C4)、单烷基氨基(C1-C4)或二烷基氨基,其中每个烷基最多有 4 个碳原子,R2 是烷基(C1-C3);或其药理学上可接受的酸加成盐。
  • 3-Amino-5-(substituted)-2 (1H) pyridinones and 3-cyano compounds useful as cardiotonics and preparation thereof
    申请人:STERLING DRUG INC.
    公开号:EP0061774A2
    公开(公告)日:1982-10-06
    1-R1-3-amino-5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridi- nones or salts thereof, which are useful as cardiotonics, where R, is hydrogen, lower-alkyl, or lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and, R' and R" are each hydrogen, hydroxy or amino at least one of R' or R" being other than hydrogen, are prepared by reacting the corresponding 3-carbamyl compound with a reagent capable of converting carbamyl to amino or by first reacting the corresponding 3-carbamyl compound where R' and R" are each hydrogen, nitro or lower-alkoxy with a reagent capable of converting carbamyl to amino and then reacting the resulting 3-amino compound where R' and/or R" are/is lower-alkoxy and/or nitro with a reagent capable of converting lower-alkoxy to hydroxy and/or with a reagent capable of converting nitro to amino. Preparation of the corresponding 3-carbamyl and 3-cyano compounds are described. The invention also concerns the 3- and/or 4-methoxy intermediates and certain novel 3-cyano analogs. Cyano compounds are also useful as cardiotonics.
    1-R1-3-氨基-5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶-壬烷或其盐,可用作强心剂,其中 R 是氢、低级烷基或低级羟基烷基,R 是氢或低级烷基,R'和 R "各自是氢、羟基或氨基,R'或 R "中至少有一个不是氢、将相应的 3-氨基甲酰基化合物与能将氨基甲酰基转化为氨基的试剂反应,或先将 R' 和 R "均为氢、硝基或低级烷氧基的相应 3-氨基甲酰基化合物与能将氨基甲酰基转化为氨基的试剂反应,然后将所得 R' 和/或 R "为/或低级烷氧基和/或硝基的 3-氨基化合物与能将低级烷氧基转化为羟基的试剂和/或能将硝基转化为氨基的试剂反应,制备 3-氨基甲酰基化合物。本发明描述了相应的 3-氨基甲酰基和 3-氰基化合物的制备方法。本发明还涉及 3-和/或 4-甲氧基中间体和某些新型 3-氰基类似物。氰基化合物还可用作强心剂。
  • US4209626A
    申请人:——
    公开号:US4209626A
    公开(公告)日:1980-06-24
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐